Yes. This is still less specific than Bisantrene (IC50 of 480nM verses 142nM for Bisantrene), but the major problem is this is right back at the beginning of the drug development process (i.e. Preclinical). I am certain that better FTO inhibitors will be found, what give Bisantrene so much value is the clinical data we have that gives us a 4 to 5 year headstart.
Pillar 1 - FTO (new thread), page-904
-
- There are more pages in this discussion • 2,071 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |